Korean Researchers Pioneer Saliva Test for Early Diagnosis of Neurological Disorders

A team of Korean researchers has developed a technology for the early diagnosis of major neurological disorders, including epilepsy, Parkinson's disease, and schizophrenia, using a small amount of saliva. This groundbreaking development promises a less invasive and more accessible diagnostic method.

Research Collaboration and Publication

The study was a joint effort by Dr. Sung-Gyu Park's team at the Korea Institute of Materials Science (KIMS), Prof. Ho Sang Jung's team at Korea University, and researchers from The Catholic University of Korea's College of Medicine. Their significant findings were published in the prestigious journal Advanced Materials.

Advanced Diagnostic Platform Details

The collaborative research team successfully developed a Galvanic Molecular Entrapment (GME)–SERS platform.

This platform directly detects structural changes in proteins using saliva, offering an alternative to traditional diagnostic methods that rely on blood or cerebrospinal fluid, which are often costly and invasive.

The innovative technology leverages plasmonic "hotspots" that form when specific proteins are captured on specialized nanostructures composed of copper oxide and gold (Au–CuO).

Mechanism and High Sensitivity

A key feature of the platform is its ability to amplify the weak Raman signals of biomolecules by over a billion times.

This allows the system to sensitively distinguish between protein fibrillation states (monomers versus fibrils), a capability that has been challenging with conventional diagnostic techniques.

This distinction based on protein structural changes is crucial for understanding the fundamental pathology of neurological disorders.

Validation and High Accuracy

To validate its efficacy, saliva samples from 44 patients with epilepsy, schizophrenia, and Parkinson's disease, alongside 23 healthy control individuals, were analyzed in collaboration with St. Vincent's Hospital.

The technology demonstrated high accuracy, exceeding 90% and reaching up to 98%, in classifying these disorders.

The ability to differentiate neurological disorders based on fundamental pathological indicators, specifically structural changes in proteins, rather than total protein concentration, has been noted as a significant global achievement.

Future Outlook and Commercialization

Dr. Sung-Gyu Park, the study's principal researcher, highlighted the technology's impact:

"The technology enables the assessment of brain disease conditions through simple saliva analysis, potentially reducing the need for expensive PET imaging or cerebrospinal fluid testing."

Prof. Ho Sang Jung further noted the technology's potential for broader application, including home-based diagnostic devices, due to its non-invasive and low-cost nature. The research team is committed to pursuing commercialization by developing portable Raman sensor–based point-of-care diagnostic devices and facilitating technology transfer to relevant companies.